Traynor Capital Management, Inc. Prothena Corp Public LTD CO Transaction History

Traynor Capital Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 24, 2019	SELL	$8.73 - $13.74 $212,575 - $334,569	-24,350 Closed	0 $0
Q3 2018 Oct 24, 2018	BUY	$12.7 - $15.79 $53,975 - $67,107	4,250 Added 21.14%	24,350 $318,000
Q2 2018 Aug 03, 2018	BUY	$10.99 - $44.21 $220,899 - $888,621	20,100 New	20,100 $303,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Traynor Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Traynor Capital Management, Inc. with notifications on news.